RBC keeps USD 9.00 target for Bausch Health stock

Published on 10/15/2026 at 22:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bausch Health will report third-quarter results on October 28, 2026. Bausch Health stock costs EUR 5.63 on October 15, 2026 at 10:15 p.m. CEST.

Target and trading date

Royal Bank of Canada reissued its USD 9.00 target on October 8, 2026.
Bausch Health will present third-quarter results on October 28, 2026.
Bausch Health stock costs EUR 5.63 at Lang & Schwarz on October 15, 2026 at 10:15 p.m. CEST, while the NYSE quote was USD 6.31.
The company had a USD 2.4 billion market capitalization and a negative P/E ratio of minus 2.14.

BHC, CA0717341071, Illustration mit AI erstellt.

Royal Bank of Canada reissued a Sector Perform rating and a USD 9.00 price target for Bausch Health on October 8, 2026, according to MarketBeat. Against the USD 6.31 NYSE quote on October 15, 2026, that target is 42.63 percent above the price. At Lang & Schwarz, Bausch Health stock was trading at EUR 5.63 on October 15, 2026 at 10:15 p.m. CEST; the NYSE quote was USD 6.31 at 3:59 p.m. ET, up 7.13 percent from USD 5.89.

Results date is October 28

Bausch Health plans to present its third-quarter 2026 results on October 28, 2026, at 5:00 p.m. EDT. The date is listed on the company's investor-relations page, which also identifies Bausch Health Companies Inc. as a diversified pharmaceutical group with operations spanning gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics and eye health. Bausch Health gives the October 28 presentation as its next quarterly reporting event.

Price remains below yearly high

The NYSE quote of USD 6.31 on October 15, 2026 stood between the 52-week low of USD 4.33 and the 52-week high of USD 8.00. The high was 26.78 percent above the quote, while the low was 31.38 percent below it. MarketBeat reported a 50-day moving average of USD 6.16 and a 200-day moving average of USD 5.58 in its October 15 report.

Valuation and company scale

Finance figures put Bausch Health's market capitalization at USD 2.4 billion on October 15, 2026 and its trailing P/E ratio at minus 2.14. The same quote showed no dividend yield. The company's second-quarter 2026 revenue was USD 2.852 billion, while net income attributable to common shareholders was USD 258.0 million for that period. Operating cash flow reached USD 670.0 million in the second quarter.

Comparison with peers

BHC (NYSE, USD): plus 7.13 percent, P/E minus 2.14, market capitalization USD 2.4 billion.

AbbVie (NYSE, USD): plus 0.58 percent, P/E 79.84, market capitalization USD 500.8 billion.

Teva Pharmaceutical (NYSE, USD): plus 0.96 percent, P/E 69.57, market capitalization USD 47.9 billion.

What the target leaves ahead

RBC's USD 9.00 target is materially above the current NYSE quote, but the latest price also remains below the USD 8.00 52-week high. The October 28 results date gives investors the next fixed point for testing revenue, earnings and cash generation.

At Lang & Schwarz, Bausch Health stock was trading at EUR 5.63 on October 15, 2026 at 10:15 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Bausch Health stock.